BEYOND TYPE 1 AND TYPE 2 DIABETES – THERE’S MORE TO THE STORY (DC-021)

Saturday, October 28, 2023

14:00 – 15:00 EST

Location: Palais, 517A

Presenter(s)

Alexander Abitbol, MDCM, FRCPC

Endocrinologist & Assistant Medical Director
LMC Healthcare
Julie A. Gilmour, MBChB, MSc (HQ), FRCPC

Endocrinologist
St. Michael's Hospital
University of Toronto
Christine Orr, B.Sc., MD, M.Sc., FACP, FRCPC (she/her/hers)

Endocrinologist
Eastern Health, Memorial University
Memorial University
CY

Catherine Yu, MD, FRCPC, MHSc, BSc (she/her/hers)

Staff Endocrinologist
St. Michael's Hospital
Department of Medicine, University of Toronto

Chair(s)

Michelle Corcoran, RD CDE (she/her/hers)

Diabetes Outreach Case Manager
Horizon Health Network

Disclosure(s):

Alexander Abitbol, MDCM, FRCPC: Abbott: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Amgen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Astra Zeneca: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Boehringer-Ingelheim: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); CCRN: Speaker/Honoraria (Ongoing); CPD Network: Speaker/Honoraria (Ongoing); Dexcom: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Eli Lilly: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Insulet: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Janssen: Consultant/Advisory Board (Ongoing), Speaker/Honoraria (Ongoing); Moderna: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Consultant/Advisory Board (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); Pfizer: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Senseonics: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Zucara: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Julie A. Gilmour, MBChB, MSc (HQ), FRCPC: No financial relationships to disclose

Christine Orr, B.Sc., MD, M.Sc., FACP, FRCPC: No financial relationships to disclose

Catherine Yu, MD, FRCPC, MHSc, BSc: No financial relationships to disclose

Michelle Corcoran, RD CDE: No relevant disclosure to display

Learning Objectives / Objectifs d'apprentissage:

At the end of this session participants will be able to / Au terme de cette conférence, vous serez:

Distinguish between atypical diabetes types of MODY, LADA and Double diabetes and examine management strategies that can impact outcomes.
Describe diabetes in cystic fibrosis and its presentation, management and optimal treatment options.
Examine diabetes secondary to pancreatitis/ pancreatectomy and differentiate the management of pancreatogenic diabetes (type 3C)
Identify management strategies for corticosteroid-induced hyperglycemia